Abstract: System comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, wherein the package is suitable and intended for receiving the replacement cap.
Type:
Grant
Filed:
March 11, 2020
Date of Patent:
June 28, 2022
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
Jurgen Pfrang, Andreas Gorshofer, Marta Lombardini
Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
Abstract: The invention relates to compounds of formula (I) inhibiting phosphoinositide 3-kinases (PI3K), to pharmaceutical compositions comprising them and therapeutic use thereof in the treatment of disorders associated with PI3K enzymes.
Type:
Application
Filed:
March 24, 2020
Publication date:
June 9, 2022
Applicant:
CHIESI FARMACEUTICI S.P.A.
Inventors:
Matteo BIAGETTI, Paolo RONCHI, Claudio FIORELLI, Paolo BRUNO
Abstract: System comprising a pre-fillable syringe with a syringe barrel and a syringe tip and a package suitable and intended for receiving the pre-fillable syringe, wherein the syringe tip is provided with a tip cap, wherein the system comprises a replacement cap for the pre-fillable syringe, wherein the package is suitable and intended for receiving the replacement cap.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
June 7, 2022
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
Jurgen Pfrang, Andreas Gorshofer, Marta Lombardini
Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
Type:
Grant
Filed:
August 2, 2016
Date of Patent:
June 7, 2022
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
Abstract: The invention relates to compounds of formula I inhibiting Rho Kinase that are tyrosine analogues derivatives, processes of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Type:
Grant
Filed:
December 14, 2018
Date of Patent:
May 17, 2022
Assignee:
CHIESI FARMACEUTICI S.P.A.
Inventors:
Alessandro Accetta, Fabio Rancati, Christine Edwards, Andrea Nuzzi
Abstract: A device (100) for facilitating the positioning of a catheter for the delivery of liquid medicament to spontaneously breathing patient, including: —an elongated main body (101) shaped to follow the internal shape of the patient's upper airways, the elongated main body (101) being provided with guiding means (107) adapted to house a catheter; —a substantially ring-shaped terminal element (103) adapted to engage the internal wall of the patient's retro-pharynx, the substantially ring-shaped terminal element (103) being connected to the elongated main body (101) by means of at least one spoke (105), the substantially ring-shaped element (103) and the at least one spoke (105) creating a chamber where the medicament can be delivered through the catheter.
Abstract: The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and/or prevention of stent thrombosis in pediatric patients undergoing stent implantation.
Abstract: A laryngeal mask airway device includes an airway tube and a laryngeal mask placed at a distal end of the airway tube. The distal end of the airway tube opens inside the laryngeal mask. The device includes a connector placed at a proximal end of the airway tube. The connector is in fluid communication with the laryngeal mask through the airway tube and is configured to be connected to a ventilation equipment. The device includes a movable element placed in the laryngeal mask and configured to steer a tip of a catheter passing through the airway tube. The device further includes a control element mounted on the proximal end of the airway tube and a motion transmission device operatively connected to the movable element and to the control element to move the movable element and to steer the tip of the catheter by acting on the control element.
Type:
Application
Filed:
November 29, 2019
Publication date:
April 14, 2022
Applicant:
Chiesi Farmaceutici S.P.A.
Inventors:
John Kenneth HAINSWORTH, George Robert BUTCHER, Peter Ryan SMITH
Abstract: The present invention is directed to the use of cangrelor for the treatment and/or prevention of shunt thrombosis in patients suffering congenital heart diseases undergoing shunt surgery. The invention is also directed to the use of cangrelor for the treatment and/or prevention of stent thrombosis in pediatric patients undergoing stent implantation.
Abstract: Administering a pulmonary surfactant and a corticosteroid is effective for the treatment of evolving bronchopulmonary dysplasia (BPD) in preterm neonates.
Abstract: The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.
Type:
Application
Filed:
September 14, 2021
Publication date:
January 13, 2022
Applicant:
Chiesi Farmaceutici S.p.A.
Inventors:
Clive Arthur Arculus-Meanwell, Simona Skerjanec
Abstract: A device (100) for facilitating the positioning of a catheter for the delivery of liquid medicament to spontaneously breathing patient, including: —an elongated main body (101) shaped to follow the internal shape of the patient's upper airways, the elongated main body (101) being provided with guiding means (107) adapted to house a catheter; —a substantially ring-shaped terminal element (103) adapted to engage the internal wall of the patient's retro-pharynx, the substantially ring-shaped terminal element (103) being connected to the elongated main body (101) by means of at least one spoke (105), the substantially ring-shaped element (103) and the at least one spoke (105) creating a chamber where the medicament can be delivered through the catheter.
Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.
Type:
Application
Filed:
June 16, 2021
Publication date:
January 6, 2022
Applicants:
Chiesi Farmaceutici S.p.A., HOSPIRA, INC.
Inventors:
Rajeshwar MOTHERAM, Gopal KRISHNA, Min DING, Keith FLOOD, Kornepati RAMAKRISHNA
Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.
Type:
Grant
Filed:
November 20, 2019
Date of Patent:
January 4, 2022
Assignee:
CHIESI FARMACEUTICI S.P.A.
Inventors:
David Andrew Lewis, Brian John Meakin, Gaetano Brambilla
Abstract: The method and system according to preferred embodiments of the present invention allows an effective delivery of aerosolized medicament (e.g., a surfactant) to the patient's lungs. According to a preferred embodiment, the method of the present invention provides an efficient delivery of the aerosol medicament (possibly breath synchronized). A glass vial in which medicaments are usually stored and shipped is used directly as a component of the system. Its function in the system is that of an intermittently pressurized chamber that can inject the surfactant into the catheter of the atomizer device. According to a preferred embodiment the delivery can be done in phase with the beginning of each inspiration. The main elements of the system are: a source of compressed gas, the already mentioned medicament vial, a catheter, and optionally means to detect the breathing pattern and a control unit.
Abstract: The system allows optimizing the dispensing of aerosol medicaments. In particular the system allows the administration of an exogenous pulmonary surfactant to very young patients (e.g. preterm neonates). A catheter (101) conveys atomized surfactant directly to the retropharyngeal region in order to increase efficiency of the medicament administration without being invasive: this is particularly important for very young patients, such as pre-term born neonates suffering from neonatal Respiratory Distress Syndrome (nRDS). The catheter is made of biocompatible flexible material (e.g. plastic material). It is possible to couple the catheter with a rigid scaffolding (e.g. metallic) to increase stiffness of the device and to improve easiness of positioning operations. The delivery of the atomized medicament is done by means of an air blasting technique.
Type:
Grant
Filed:
October 16, 2014
Date of Patent:
December 14, 2021
Assignee:
CHIESI FARMACEUTICI S.p.A.
Inventors:
Raffaele Dellaca, Ilaria Milesi, Mario Di Cecio, Roger Fane Sewell, Donal Joseph Taylor